Advertisement

Related Videos

Welcome and Introduction to Vi3C

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Advertisement

Advertisement




Aug
11
Today In Oncology
Outreach to HCT Recipients, Primary Care Doctors May Reduce Skin Cancer Risk
American College of Surgeons Commission on Cancer Introduces Rural Cancer Program Accreditation
Phase III Trial Supports Intensified Total Neoadjuvant Therapy in High-Risk Rectal Cancer
Teclistamab Improves Progression-Free and Overall Survival in Previously Treated Multiple Myeloma
Oral Nicotinamide May Offer Cost-Effective Prevention of Keratinocyte Carcinoma
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo